RGD Reference Report - New concepts in calcium-sensing receptor pharmacology and signalling. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

New concepts in calcium-sensing receptor pharmacology and signalling.

Authors: Ward, DT  Riccardi, D 
Citation: Ward DT and Riccardi D, Br J Pharmacol. 2012 Jan;165(1):35-48. doi: 10.1111/j.1476-5381.2011.01511.x.
RGD ID: 7207238
Pubmed: PMID:21627634   (View Abstract at PubMed)
PMCID: PMC3252964   (View Article at PubMed Central)
DOI: DOI:10.1111/j.1476-5381.2011.01511.x   (Journal Full-text)

The calcium-sensing receptor (CaR) is the key controller of extracellular calcium (Ca(2+)(o)) homeostasis via its regulation of parathyroid hormone (PTH) secretion and renal Ca(2+) reabsorption. The CaR-selective calcimimetic drug Cinacalcet stimulates the CaR to suppress PTH secretion in chronic kidney disease and represents the world's first clinically available receptor positive allosteric modulator (PAM). Negative CaR allosteric modulators (NAMs), known as calcilytics, can increase PTH secretion and are being investigated as possible bone anabolic treatments against age-related osteoporosis. Here we address the current state of development and clinical use of a series of positive and negative CaR modulators. In addition, clinical CaR mutations and transgenic mice carrying tissue-specific CaR deletions have provided a novel understanding of the relative functional importance of CaR in both calciotropic tissues and those elsewhere in the body. The development of CaR-selective modulators and signalling reagents have provided us with a more detailed appreciation of how the CaR signals in vivo. Thus, both of these areas of CaR research will be reviewed.


Additional Information